NAPSRx

Johnson & Johnson (NYSE: JNJ) will spend $200 million for further expansion on their Ebola vaccine program at Janssen Pharmaceuticals.

The Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) to the US Food and Drug Administration (FDA) made a unanimous decision to support the approval of Novartis’ investigational selective interleukin-17A (IL-17A) inhibitor, AIN457...

There are many reasons why pharmaceutical sales positions are desired by many aspiring job seekers in the healthcare industry.

Roche revealed an impressive financial report for their third quarter with notable sales growth in the pharmaceuticals division.  Group sales were 11.78 billion Swiss francs ( $12.5 billion) up 5% compared to last year.

The U.S. Food and Drug Administration has approved two new therapies for the treatment of idiopathic pulmonary fibrosis (IPF) these are Roche’s Esbriet (pirfenidone) and Boehringer Ingelheim’s  OFEV™ (nintedanib*).

Astellas Pharma Inc and an investigator at Harvard Medical will collaborate on discovering the pathologic mechanism and identifying therapeutic treatments for retinitis pigmentosa.

Johnson & Johnson (NYSE: JNJ) has announced their third quarter earnings for 2014 with sales amounting to $18.5 billion, up 5.1% versus the third quarter of 2013.

The United States Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for Pfizer's palbociclib. The NDA submitted requests approval of palbociclib, in combination with letrozole.

According to the Decisions Resources Group, the chronic heart failure market will grow from approximately $2.9 billion in 2013 to $8.9 billion in 2023.

Benralizumab, AstraZeneca’s novel investigational monoclonal antibody to treat patients with severe, uncontrolled asthma and elevated levels of eosinophils (inflammatory white blood cell)  has produced optimistic safety and efficacy clinical data...